Madrigal Announces Additional Positive MAESTRO-NASH Data; Bluebird Sells Second PRV to BMS for $95M
Two cardiometabolic-related new items have been observed: Madrigal Pharmaceuticals announced additional positive results from the pivotal Ph3 MAESTRO-NASH trial evaluating resmetirom in patients with NASH and liver fibrosis (view press release; CT.gov record); and bluebird bio announced it entered into a definitive agreement to sell its second Rare Disease PRV to BMS for $95M (view press release; view 8-K). Below, FENIX provides highlights and insights for the respective news items, including updated thoughts on the resmetirom filing discrepancy.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.